Healthcare Services

Global Hemophilia Market to Reach $23.16B by 2030 with 9.3% CAGR

April 22, 2026April 26, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Anticipated Rise In Market Value Of The Hemophilia Market During The Forecast Period?

The size of the hemophilia market has experienced robust expansion over recent years. This market is projected to expand from $14.98 billion in 2025 to $16.21 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 8.2%. Historically, this growth can be attributed to several factors, including improved availability of clotting factor concentrates, expansion of prophylactic treatment adoption, growth in hemophilia awareness programs, advancements in recombinant factor production, and increased access to specialized care centers.

The hemophilia market is expected to demonstrate robust growth over the next few years, projected to reach $23.17 billion by 2030, expanding at a compound annual growth rate of 9.3%. This anticipated growth is fueled by an increase in gene therapy approvals, a rising adoption of personalized treatment approaches, the expansion of home infusion programs, growing investments in rare disease research, and an increased focus on improving quality of life. Major trends in the forecast period are set to include the wider adoption of long-acting clotting factor therapies, a heightened emphasis on gene therapy for hemophilia, the increasing use of home-based treatment regimens, the expansion of personalized prophylactic treatment plans, and enhanced integration of digital patient monitoring.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/hemophilia-global-market-report

Which Key Drivers Are Affecting The Hemophilia Market Development?

The increasing prevalence of genetic abnormalities is anticipated to propel the growth of the hemophilia market. Genetic abnormalities, also referred to as genetic mutations or disorders, involve changes in an individual’s DNA sequence that can result in various health conditions and physical traits. Hemophilia treatment focuses on preventing or controlling bleeding episodes, minimizing complications, and improving the quality of life for those affected by genetic abnormalities. For instance, in October 2024, data from the Cystic Fibrosis Trust, a UK-based charity dedicated to supporting people with cystic fibrosis, indicated that in 2022, approximately 11,148 cystic fibrosis (a genetic disorder) patients were registered, a figure that increased to 11,318 in 2023, signifying a 1.5% rise in patient registrations year over year. Consequently, the rising occurrence of genetic abnormalities is a key driver for the expansion of the hemophilia market.

What Are The Main Segments Within The Hemophilia Market Segment Structure?

The hemophilia market covered in this report is segmented –

1) By Type: Hemophilia A, Hemophilia B, Hemophilia C, Other Types

2) By Treatment: Replacement Therapy, Hemostatic Agents, Desmopressin, Gene Therapy, Other Treatments

3) By End-User: Hospitals, Clinics, Home Care Settings, Other End-Users

Subsegments:

1) By Hemophilia A: Severe Hemophilia A, Moderate Hemophilia A, Mild Hemophilia A

2) By Hemophilia B: Severe Hemophilia B, Moderate Hemophilia B, Mild Hemophilia B

3) By Hemophilia C: Severe Hemophilia C, Mild Hemophilia C

4) By Other Types: Acquired Hemophilia, Von Willebrand Disease

What Trends Are Transforming The Hemophilia Market?

Major companies operating in the hemophilia market are developing cutting-edge drugs like ALTUVIIIO to sustain their competitive edge. For instance, in February 2023, Sanofi S.A., a pharmaceutical and healthcare company based in France, launched ALTUVIIIO for hemophilia, which had received approval from The Food and Drug Administration (FDA), a US-based government agency. With a once-weekly dosing regimen, ALTUVIIIO stands as the initial and sole hemophilia A medication designed to provide regular to near-normal factor activity levels (above 40%) for most of the week, significantly diminishing bleeding compared to prior factor VIII prophylaxis.

Who Are The Companies Participating In The Hemophilia Market?

Major companies operating in the hemophilia market are Kedrion S.p.A., Chugai Pharmaceutical Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Baxter International Inc., CSL Limited, Biogen Inc., Grifols S.A., Octapharma AG, BioMarin Pharmaceutical Inc., GC Pharma, Alnylam Pharmaceuticals Inc., Bio Products Laboratory Ltd., Sangamo Therapeutics Inc., UniQure, Intellia tx, ProMetic BioSciences Ltd., Dimension Therapeutics, Amarna therapeutics, HEMA Biologics LLC, Aptevo Therapeutics, Arcturus Therapeutics Inc., Ferring Lakemedel AB, Chiesi Farmaceutici S.p.A.

Get The Full Hemophilia Market Report:

https://www.thebusinessresearchcompany.com/report/hemophilia-global-market-report

Which Region Leads The Hemophilia Market In Overall Market Size?

North America was the largest region in the hemophilia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemophilia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Hemophilia Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/hemophilia-global-market-report

Browse Through More Reports Similar to the Global Hemophilia Market 2026, By The Business Research Company

Hemostasis Products Market Report 2026

https://www.thebusinessresearchcompany.com/report/hemostasis-products-global-market-report

Hepatitis Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report

Acquired Hemophilia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/acquired-hemophilia-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795